Product Description
For Treatment of chronic pain (Sourced from: https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Frezatomidine.pdf)
Mechanisms of Action: ADRA1A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Myofascial Pain Syndromes|Fibromyalgia|Cystitis, Interstitial|Pain Unspecified|Irritable Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-006100-11 | P2 |
Completed |
Fibromyalgia |
2009-10-27 |
|
NCT00441766 | P2 |
Terminated |
Irritable Bowel Syndrome |
2008-02-01 |
|
NCT00445705 | P2 |
Terminated |
Myofascial Pain Syndromes|Fibromyalgia |
2008-01-01 |
|
NCT00381719 | P2 |
Completed |
Pain Unspecified |
2007-11-01 |